Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2022 12:05 ET | Source: Sanofi - Aventis Groupe

Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes de l’œsophagite à éosinophiles

Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes de l’œsophagite à...
February 26, 2022 12:05 ET | Source: Sanofi - Aventis Groupe

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis Dupixent 300 mg weekly is the only biologic medicine...
February 26, 2022 12:00 ET | Source: Sanofi - Aventis Groupe

Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) diminue significativement les démangeaisons et l’urticaire des patients souffrant d’urticaire chronique spontanée

Des données de phase III de dernière minute présentées au Congrès annuel de l’AAAAI 2022 montrent que Dupixent® (dupilumab) diminue significativement les démangeaisons et l’urticaire des patients...
February 26, 2022 12:00 ET | Source: Sanofi - Aventis Groupe

Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria

Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria In this Phase 3 trial, Dupixent...
February 26, 2022 10:00 ET | Source: The Rosen Law Firm PA

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SunPower Corporation Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – SPWR

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
February 26, 2022 09:21 ET | Source: The Rosen Law Firm PA

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Acutus Medical, Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – AFIB

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021...
February 26, 2022 09:10 ET | Source: The Rosen Law Firm PA

ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – FENC

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28,...
February 26, 2022 09:01 ET | Source: The Rosen Law Firm PA

ROSEN 是一家頂級律師事務所，鼓勵損失超過 10 萬美元的 FirstCash Holdings, Inc. 投資者在證券集體訴訟的重要截止日期前尋求法律意見 – FCFS

紐約, Feb. 26, 2022 (GLOBE NEWSWIRE) -- 為何：全球投資者權益律師事務所 Rosen Law Firm 提醒在 2018 年 2 月 1 日至 2021 年 11 月 12 日（包括首尾兩天）期間（「集體訴訟期間」）購買了 FirstCash Holdings, Inc. (NASDAQ: FCFS) 證券的購買者注意，2022 年 3 月 15...
February 26, 2022 09:00 ET | Source: The Rosen Law Firm PA

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Gatos Silver, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – GATO

WHY: NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Gatos...
February 25, 2022 23:28 ET | Source: Tautachrome, Inc.

Tautachrome (OTC: TTCM) Targets Criminal Stock Trolls and Forums that Protect Them

ORO VALLEY, Ariz., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Tautachrome Inc. (OTC: TTCM) today describes the direction and focus of its integrity defense activity seeking to curb stock troll criminality...